Physician profile
Anthony Knell
NPI 1972609550
$4,404.14
in general payments reported to CMS, 2019-2025
20 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.26 · 2022: $485 · 2023: $1,431 · 2024: $756 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.86 |
| Education | $141.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $678.05 | 2021-2025 | |
| Dermavant Sciences, INC. | $540.77 | 2023-2024 | Vtama |
| Lilly USA, LLC | $447.73 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $382.86 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $378.06 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $377.17 | 2022-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $249.25 | 2023-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $195.41 | 2023 | Ycanth |
| Novartis Pharmaceuticals Corporation | $182.79 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $161.74 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $133.04 | 2022-2025 | Ilumya, Winlevi |
| Genzyme Corporation | $130.18 | 2024-2025 | |
| Ucb, INC. | $122.80 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $116.44 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $115.09 | 2023-2025 | Sotyktu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.36 | 2025 | Vtama |
| Leo Pharma INC. | $52.20 | 2023 | Adbry |
| Pfizer INC. | $42.59 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.17 | 2022 | |
| Biofrontera INC. | $11.44 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Knell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.